News for Xencor, Inc. (XNCR)

MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ('Knight') a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (FL). The supplemental application for the additional indication was selected for review under Project Orbis.

LONDON and PHILADELPHIA, July 01, 2025 (GLOBE NEWSWIRE) -- Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor in business development. Dr. Liebowitz will lead the Company’s clinical strategy and execution as it continues to advance its pipeline of targeted cancer therapies and Mr. Bogatyrenko will add additional strength to the Group’s business development strategy.

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytoly

Founded in 2008, Caris specializes in precision oncology and helps diagnose cancer through its tumor profiling and blood-based cancer diagnostics. The company, whose rivals include Roche's Foundation Medicine, Guardant Health, and Grail, generates a majority of its revenue from its tissue-based molecular profiling which helps select the appropriate cancer therapy. In 2021, Caris raised $830 million at a $7.83 billion valuation in a Sixth Street-led funding round.

Incyte (Nasdaq:INCY) today announced that data from numerous programs in its hematology/oncology portfolio will be presented at the 2025 European Hematology As

On May 8, 2025, Barclays analyst Peter Lawson released a new analyst note concerning Xencor (XNCR), maintaining the stock rating at "Underweight." The decision

PR NewswireTHOUSAND OAKS, Calif., May 1, 2025 THOUSAND OAKS, Calif., May 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for

Xencor (XNCR) has revealed favorable interim outcomes from its pioneering study of XmAb942, a potent investigational anti-TL1A antibody aimed at treating inflam

Incyte (Nasdaq:INCY) today reports 2025 first quarter financial results, and provides a status update on the Company's clinical development portfolio.

William Blair has begun coverage of Xencor (XNCR) with an Outperform rating, highlighting the promising prospects of the biopharmaceutical manufacturer. The fir

Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced to…

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, to

Comprehensive SWOT analysis based on Xencor Inc's latest SEC 10-K filing.Detailed examination of Xencor Inc's competitive positioning and future prospects.Data

Xencor (XNCR) delivered earnings and revenue surprises of 25.30% and 293.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Xencor Inc (XNCR), a clinical-stage biopharmaceutical company specializing in engineered antibodies for cancer and autoimmune diseases, announced its financial

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, to

Xencor (XNCR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Xencor has a strong cash position, bolstered by a recent $200 million secondary offering. Its pipeline has promise, but progress has been notably slow. Read more here.